Kairos Pharma Ltd. Reports Promising Safety Results for ENV-105 in Phase 2 Prostate Cancer Trial

Kairos Pharma Ltd. (NYSE American: KAPA) has shared interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab), targeting metastatic castration-resistant prostate cancer. The initial findings from the first ten patients indicate no dose-limiting toxicities or unexpected adverse events, with ENV-105 showing good tolerance when combined with apalutamide, a standard hormone therapy. This progress is significant, as it suggests ENV-105 could offer a safe and effective treatment avenue for a particularly aggressive form of prostate cancer.

The trial, conducted at leading institutions such as Cedars-Sinai, City of Hope, and Huntsman Cancer Center, plans to enroll 100 patients, with interim efficacy data expected by September 2025. The favorable safety profile of ENV-105, a pioneering CD105 antagonist, may lead to a Phase 3 study, subject to regulatory approval. This development marks a notable step forward in cancer treatment, especially for patients with few therapeutic options.

ENV-105's mechanism of action focuses on CD105, a protein linked to resistance against various cancer treatments. By targeting CD105, ENV-105 offers a novel strategy to combat drug resistance, potentially enhancing patient outcomes. The trial's success could extend beyond prostate cancer, impacting the treatment of other cancers where CD105 contributes to disease progression and therapy resistance.